The
global Acne Drugs Market size is expected to reach USD
5.9 billion by 2025, according to a new report by Grand View Research, Inc.,
registering a 4.2% CAGR during the forecast period. Several factors such as
emergence of biologics, unhealthy lifestyle, and rising disease incidence are
anticipated to drive the market.
Acne
vulgaris is one of the most common dermatological disorders, affecting 9.4%
people worldwide. Although the condition can affect people of all ages, it is
most prevalent among teenagers. It has been found that the condition is
prevalent in more than 85.0% people between the ages of 12 and 25. Acne can
appear in forms ranging from comedones to cystic lesions, depending on its
severity.
Retinoids
and antibiotics remain the mainstays of acne treatment. Retinoids led the
therapeutic classes in 2017, and it is expected to continue this trend through
2025. The therapeutic landscape is witnessing a shift toward combination
treatment due to higher efficacy, convenient dosing, and fewer adverse effects.
By
mode of administration, topical drugs currently dominate the market. Severe
cases see the use of systemic medications such as oral antibiotics, hormonal
agents, or other drugs. However, emergence of biologics (Gevokizumab and
RA-18C3) will fuel the injectable route of administration. Biologics offer
improved clinical advantage over conventional topical treatments since they
target inflammatory mechanisms with disease modifying ability.
Discontinuation
or termination of key pipeline candidates on account of unsuccessful clinical
trials is a major restraint this market faces. Upon launch, Olumacostat
glasaretil (Dermira; topical lipid synthesis inhibitor) was expected to be the
first topical anti-acne drug with isotretinoin-like results without significant
side effects. However, the drug failed to meet clinical endpoints, leading to
discontinuation in March 2018. Similarly, SNA-001 (Sienna; silver nanoparticles
solution) was deemed unsuccessful in two key trials wherein it was tested in
conjunction with 810nm and 1064nm lasers in July 2018. Thesan withdrew TSN2898
from Phase II trials due to drug unavailability. Xenon discontinued development
of XEN801 after the drug failed Phase II clinical trials.
Despite
being one of the most common dermatological diseases in the world, innovation
in acne treatment has been rather limited over the past decade. Drug companies
are currently exploring novel treatment approaches including stearoyl CoA
desaturase inhibition, melanocortin receptor antagonism, and anti-IL-1 monoclonal
antibodies. Impending launch of late-stage pipeline products indicate a
promising future for the global acne drugs market.
Browse
Details of Report @
https://www.grandviewresearch.com/industry-analysis/acne-drugs-market
https://www.grandviewresearch.com/industry-analysis/acne-drugs-market
Further key findings from the report suggest:
- By type,
inflammatory acne captured more than 50.0% of the market in 2017.
Comedonal acne were ranked second-largest, among other types
- On the basis
of therapeutic class, retinoids led the market in 2017, followed by
antibiotics. This trend is likely to continue through 2025
- The
treatment paradigm is shifting toward combination therapies and biologics.
Combination products are gaining traction due to higher efficacy,
convenient dosing, and fewer adverse effects
- Topical
products dominated the treatment landscape, based on mode of
administration. However, introduction of biologics is likely to result in
the growth of the injectables segment
- U.S.
dominated the major markets and is projected to maintain its lead through
2025, owing to rising disease incidence and ease of access to anti-acne
products
- Allergan,
Bayer, Galderma, Stiefel, and Valeant are some key players operating in
this market. Valeant is projected to lead the market in 2025 due to higher
adoption of Retin-A micro as well as anticipated launch of pipeline
candidates.
About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/
No comments:
Post a Comment